High Potency Active Pharmaceutical Ingredients (HPAPI) Market Outlook To 2024
The global high potency active pharmaceutical Ingredients (HPAPI) Market was valued at $14.36 billion in 2016 and is forecast to grow at a steady CAGR of 8.4% between 2017 and 2024, culminating in 2024 global revenue of $27.33 billion.
Industry at a Glance
High potency active pharmaceutical ingredients has emerged as one of the fastest growing segments within the global pharmaceutical industry. It offers high growth potential in upcoming years due to strong demand from anti-cancer drugs along with increasing usage in cardiovascular drugs. These ingredients possess selective targeting characteristics that enables their deployment in treatment of cancer. Rising demand for HPAPI's can be attributed towards growth of oncology therapeutics market in the recent years. An API is considered to be a HPAPI, if it has an occupational exposure limit at below 10 microorganisms per cubic meter of air. Increasing usage in form of Antibody Drug Conjugates (ADC), which is further deployed in significant and effectual development of cancer treatment.
Click the link below to view the report description:
Key findings from the study: -
o The global HPAPI market was valued at $13.26 bn in 2015 and is forecast to grow at a steady CAGR of 8.6% between 2015 and 2024, culminating in 2024 global sales of $27.80 bn.
o Major HPAPI applications include hormonal balance, oncology, glaucoma and other emerging application such as gynecological and cosmetic applications. Increasing number of cancer patients across the globe has increased demand from oncology application segment.
o Key industry participants operating in the global market include Lonza Group, BASF AG, Covidien PLC, Novartis International AG, Carbogen Amcis AG, Hospira Inc, Pfizer Inc., Abbvie Inc., Mylan N.V., Neuland Laboratories, Hikal, Merck & Co., Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim, and Teva Pharmaceuticals Industries Ltd.
o North America individually accounted for over 42% of the overall market revenue in 2016. Asia pacific market is expected to grow at a steady rate owing to increasing production of generic drugs in countries such as China and India along with rapidly improving healthcare facilities.
Ameri Research has segmented the High Potency Active Pharmaceutical Ingredients (HPAPI) Market by material categories, product type, end-use and region:
o High Potency Active Pharmaceutical Ingredients (HPAPI) Market by Product (Revenue, USD Million)
o High Potency Active Pharmaceutical Ingredients (HPAPI) Market by Type (Revenue, USD Million)
o High Potency Active Pharmaceutical Ingredients (HPAPI) Market by Business Model (Revenue, USD Million)
o High Potency Active Pharmaceutical Ingredients (HPAPI) Market by End-Use (Revenue, USD Million)
o Hormonal Imbalance
o High Potency Active Pharmaceutical Ingredients (HPAPI) Market by Region (Revenue, USD Million)
o North America
o Asia Pacific
o Latin America
o Middle East & Africa (MEA)
o Saudi Arabia
o High Potency Active Pharmaceutical Drug Market by End-Use (Revenue, USD Million)
o Hormonal Imbalance
Ameri Research Inc.
Ameri Research Inc. (www.ameriresearch.com) is a U.S. based market research and consulting company, registered in the State of Florida and headquartered in Tampa Bay Area. At Ameri Research we are passionately curious about people, markets, brands and society. Our ability to gauge market movements, deep expertise in data science, strong domain expertise and years of collective global experiences helps us to bring unmatched quality in deliverables to our clients. With carefully planned systems and processes in place, we cater to the requirements of our clients in a timely and cost-efficient manner, bringing increased predictability to their business. Each year we are publishing more than 100 syndicated reports in healthcare, chemicals, materials, food & beverages, defense & aerospace, media & entertainment, sports & fitness, and energy. We offer our clients a unique depth of knowledge and expertise around-
Market Entry Strategy
Developing a culture of collaboration and curiosity, we attract the highest caliber of likeminded people having ability to influence and shape the future.
Follow us on LinkedIn for our latest upcoming reports www.linkedin.com/company/ameri-research-inc./
Follow us on Facebook for our latest upcoming reports www.facebook.com/AmeriResearchInc/
Follow us on Twitter for our latest upcoming reports www.twitter.com/AmeriResearch
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release High Potency Active Pharmaceutical Ingredients (HPAPI) Market Outlook To 2024 here
News-ID: 2025624 • Views: 331
More Releases from Ameri Research Inc.
Global Stem Cell Market Outlook To 2026
Global Stem Cell Market Outlook To 2026: Key Product Categories (Adult, HESC, Induced Pluripotent), Application (Regenerative Medicine, Drug Discovery & Development), Therapy (Autologous, Allogenic), Regional Segmentation, Pricing Analysis, Pipeline Analysis, Competitive Dynamics, M&A Insights, Segment Forecast, And Conclusion The Stem Cell Market was valued at $9.10Billion in 2018 and is forecast to grow at a modest9.8 % CAGR between2018 and 2025, culminating in 2026 global sales of $17.20Billion. Increase in the
Wireless Broadband Market Outlook To 2024
Wireless Broadband Market Outlook To 2024: Key Technology Categories (LMDS, MMDS, PCS), Application (Residential, Commercial), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (IPP, OPP, RAP) And Segment Forecast The global wireless broadband market was valued at $10.6bn in 2016 and is forecast to grow at a strongCAGR of 10.6% between 2017 and 2024, culminating to global revenue of $23.5bn by 2024. Industry at a Glance With growing social media communication,
Offshore Drilling Market Outlook To 2024
Offshore Drilling Market Outlook To 2024: In-Depth Market View, Key Service Categories (Directional Drilling, Measurement While Drilling, Contract Drilling, Logging While Drilling), Application (Shallow, Deepwater, Ultra-Deep Water), Regional Segmentation, Top Players & Company Share, Competitive Dynamics, Growth Drivers & Restraints, Pricing Analysis, Segment Forecast And Key Conclusion The global offshore drilling market was valued at $89.5 billion in 2016 and is forecast to grow at a steady CAGR of 5.2% between
Global Hyaluronic Acid Market Outlook To 2026
Global Hyaluronic Acid Market Outlook To 2026: In-Depth Market Overview, Key Application Types (Dermal Fillers, Osteoarthritis [Single Injection, Three Injection, Five Injection], Ophthalmic, Vesicoureteral Reflux), Regional Segmentation, Pricing Analysis, Pipeline Analysis, Competitive Dynamics, M&A Insights, Segment Forecast, And Conclusion The Hyaluronic Acid Market was valued at $xx.9Billion in 2018 and is forecast to grow at a modestxx.6 % CAGR between2018 and 2025, culminating in 2026 global sales of $xx.7Billion. Hyaluronic Acids
More Releases for API
Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles. Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform. Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The